Emerging World Pharma Inc. Strategic Partner African Global Pharma Corp. Producing Anti-Malarial Pharmaceutical Globartem®

Emerging World Pharma Inc. strategic partner African Global Pharma Corp.(AGP) has commenced production of the anti-malarial pharmaceutical Globartem®.
Oct. 30, 2012 - PRLog -- Sunyani Ghana -- Emerging World Pharma Inc. -Emerging World Pharma Inc. strategic partner African Global Pharma Corp.(AGP) has commenced production of the anti-malarial pharmaceutical Globartem®. Globartem® is indicated for the treatment of uncomplicated malaria caused by multiple drug resistant strains of p. falciparum. AGP will produce the medicine in tablet form including a dispersible tablet for pediatric use. Each tablet contains Artemether 20mg and Lumefantrine 120mg.

African Global Pharma Gh endeavors to ensure the availability of world class, quality medicines at affordable prices and within reach. The company intends to introduce its line of over-the counter pharmaceuticals beginning November 1, 2012.

About African Global Pharma, Ghana
African Global Pharma (Ghana) Limited is an affiliated company of African Global Pharma Corp. of Canada with business partnership with the Catholic Diocese of Sunyani to distribute all our manufactured drugs to the Catholic Mission Hospitals. African Global Pharma’s production facility in Sunyani, Ghana was fully rehabilitated and built by African Global Pharma Corp, Canada. The plant and its operations are headquartered in Sunyani at the Diocesan Bldg.

For more on AGP click here

About Emerging World Pharma Inc.

Emerging World Pharma Inc. is an investor in generic based pharmaceutical companies manufacturing within developing nations.

The company focuses its investments on generic pharmaceutical companies that have contracts with three major buyer groups; church, government and wholesalers. Market research shows that these branches are the most secure, protected and reputable for the distribution of medicines.

For more on Emerging World Pharma Inc. click here http://www.emergingpharma.com/

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

Contact: Joel Everret
Emerging World Pharma Inc.
Investor Relations Division
Email: info@emergingpharma.com
Website: http://www.emergingpharma.com/
Source:Emerging World Pharma INc.
Email:***@emergingpharma.com Email Verified
Tags:Emerging World Pharma, Afircan Global Pharma, Pharmaceuticals
Industry:Consumer, Health, Science
Location:Toronto - Ontario - Canada
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse

Like PRLog?
Click to Share